The Food and Drug Administration granted breakthrough therapy designation to Arrowhead Pharmaceuticals' plozasiran drug to treat severe hypertriglyceridemia.
The designation expedites the development and review of drugs for which preliminary evidence indicates substantial improvement over available therapies to treat serious conditions.
Arrowhead intends to complete phase three clinical trials of the drug in the middle of next year and submit a supplemental new drug application by the end of 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.